Company intelligence / Profile preview

Normax

New York, New York, United States

Ownership: Private
Development stage: Other

Overview

Normax is a biotechnology company dedicated to developing and manufacturing affordable, high-quality vaccines for global health challenges, with a primary focus on infectious diseases. The company gained prominence for its "People's Vaccine" initiative, which aims to provide low-cost COVID-19 vaccines to underserved populations through a decentralized manufacturing model. Beyond COVID-19, Normax is working on a pipeline that includes candidates for tuberculosis and other high-burden diseases. Their business model emphasizes technology transfer and local production to ensure equitable access to life-saving immunizations.

Therapeutic areas: Infectious Diseases
Modalities: VaccineProteinRecombinant protein
Industry: Biotech

Drug pipeline

1 asset

RMX2001

Unknown

Partnerships

Serum Institute of IndiaGenoa Biopharmaceuticals

Beyond the preview

Go deeper on Normax.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Normax.

Explore the full profile